Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
2 reports, 2 independent
Updated Sep 3
Gone quiet
- Reports
- 2
- Developments
- 6
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK is submitting data to the FDA regarding potential expansion of its drug indications.Sub-event
GSK's drug validation process is being influenced by FDA guidance, with ties to the U.K. operations.1 source
- GSK has launched a competing ROS1 therapy, while Nuvation Bio Inc. presented relevant data at a major medical conference.Sub-event
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.Sub-event
- Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.Sub-event
GSK is involved in competitive challenges regarding lung cancer treatments while awaiting FDA decisions.1 source
Keep exploring
The entities involved
- FDA
-
GSK
British multinational pharmaceutical and biotechnology company
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.